Home » Stocks » NMTR

9 Meters Biopharma, Inc. (NMTR)

Stock Price: $1.42 USD -0.03 (-1.74%)
Updated Jun 16, 2021 10:32 AM EDT - Market open
Market Cap 377.06M
Revenue (ttm) n/a
Net Income (ttm) -63.32M
Shares Out 211.28M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $1.42
Previous Close $1.44
Change ($) -0.03
Change (%) -1.74%
Day's Open 1.43
Day's Range 1.38 - 1.45
Day's Volume 785,324
52-Week Range 0.45 - 2.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9 Meter...

2 days ago - Accesswire

RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO o...

1 week ago - Accesswire

RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO o...

2 weeks ago - Accesswire

- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-...

3 weeks ago - Accesswire

Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in ...

4 weeks ago - Accesswire

RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, Jo...

4 weeks ago - Accesswire

RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the Uni...

4 weeks ago - Accesswire

- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 followin...

1 month ago - Accesswire

RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will par...

1 month ago - Accesswire

Penny stocks continue to trend; which should you add to your watchlist? The post 3 Penny Stocks For Your ‘Doge Day' Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other stocks mentioned: XXII, YVR
1 month ago - PennyStocks

RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will en...

1 month ago - Accesswire

RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will co...

2 months ago - Accesswire

Some of the company's executives are making notable moves.

2 months ago - The Motley Fool

RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previo...

2 months ago - Accesswire

RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underw...

2 months ago - Accesswire

RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a ...

2 months ago - Accesswire

FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure  Announced posit...

2 months ago - Accesswire

Tuesday, March 23rd @ 11am Eastern Time RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announ...

3 months ago - Accesswire

- Oppenheimer 31st Annual Healthcare Conference - March 16th - 18th - Maxim Group 2021 Emerging Growth Virtual Conference - March 17th - 18th RALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Biophar...

3 months ago - Accesswire

RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Patr...

3 months ago - Accesswire

RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Micha...

3 months ago - Accesswire

9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

4 months ago - Zacks Investment Research

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CVE, CNTY, KSHB, VIVE
4 months ago - 24/7 Wall Street

NMTR stock is on the move Wednesday. Here's what you should know about 9 Meters Biopharma, which specializes in GI conditions.

5 months ago - InvestorPlace

Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-1...

5 months ago - Accesswire

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

9 Meters Biopharma (NMTR) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Shares of 9 Meters Biopharma Inc (NASDAQ: NMTR) were ripping higher following a bullish initiation by Brookline Capital Markets.

9 months ago - Benzinga

NEW YORK, July 13, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

11 months ago - PRNewsWire

9 Meters Biopharma Inc. (NASDAQ: NMTR) may not be a household name right now, but one brokerage firm sees huge potential upside.

11 months ago - 24/7 Wall Street

About NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It al... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Sandeep Laumas
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
NMTR
Full Company Profile

Financial Performance

Financial Statements